Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline (Q34604979)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline (English)

1 reference

Europe PubMed Central

3 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

13

object named as

Janet Wittes

1 reference

Europe PubMed Central

3 August 2017

H Ballentine Carter

7

object named as

H Ballentine Carter

1 reference

Europe PubMed Central

3 August 2017

Jonathan I. Epstein

9

object named as

Jonathan I Epstein

1 reference

Europe PubMed Central

3 August 2017

Barnett S. Kramer

1

object named as

Barnett S Kramer

1 reference

Europe PubMed Central

3 August 2017

author name string

Karen L Hagerty

2

1 reference

Europe PubMed Central

3 August 2017

Stewart Justman

3

1 reference

Europe PubMed Central

3 August 2017

Mark R Somerfield

4

1 reference

Europe PubMed Central

3 August 2017

Peter C Albertsen

5

1 reference

Europe PubMed Central

3 August 2017

William J Blot

6

1 reference

Europe PubMed Central

3 August 2017

Joseph P Costantino

8

1 reference

Europe PubMed Central

3 August 2017

Paul A Godley

10

1 reference

Europe PubMed Central

3 August 2017

Russell P Harris

11

1 reference

Europe PubMed Central

3 August 2017

Timothy J Wilt

12

1 reference

Europe PubMed Central

3 August 2017

Robin Zon

14

1 reference

Europe PubMed Central

3 August 2017

Paul Schellhammer

15

1 reference

Europe PubMed Central

3 August 2017

American Society of Clinical Oncology Health Services Committee

16

1 reference

Europe PubMed Central

3 August 2017

American Urological Association Practice Guidelines Committee

17

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

24 February 2009

1 reference

Europe PubMed Central

3 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

3 August 2017

27

1 reference

Europe PubMed Central

3 August 2017

9

1 reference

Europe PubMed Central

3 August 2017

1502-1516

1 reference

Europe PubMed Central

3 August 2017

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

5-alpha-reductase inhibitors for prostate cancer prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

The cost of prostate cancer chemoprevention: a decision analysis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

The influence of finasteride on the development of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Current attitudes and practice of American Society of Clinical Oncology-member clinical oncologists regarding cancer prevention and control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

7 July 2018

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Rebalancing ratios and improving impressions: later thoughts from the prostate cancer prevention trial investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

A big study yields big questions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668556

26 October 2018

Cancer prevention and the American Society of Clinical Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/19252137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19252137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19252137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19252137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19252137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride

1 reference

https://pubmed.ncbi.nlm.nih.gov/19252137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.16.9599

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34604979&oldid=2087539944"